Accueil » Communiqués de presse » Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II/III clinical study on TOTUM•63: proven efficacy on the main risk factor of developing type 2 diabetes.
Les communiqués de presse
22May2023
Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II/III clinical study on TOTUM•63: proven efficacy on the main risk factor of developing type 2 diabetes.
